CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.
Depressive Disorder, Major
About this trial
This is an interventional treatment trial for Depressive Disorder, Major focused on measuring methylphenidate hydrochloride, oral tablets, Major Depressive Disorder
Eligibility Criteria
Inclusion Criteria: Currently having a Major Depressive Disorder episode without psychotic features Has had an inadequate response to at least one but not more than 3 antidepressants given for 4 weeks Is currently treated with an antidepressant for the past 4 weeks Has a Montgomery Asberg Depression Rating Scale (MADRS) total score greater than or equal to 20, lassitude score of greater than or equal to 2 and a suicidal thought score less than 4 Has a Clinical Global Impression of Severity (CGI-S) score greater than or equal to 4 Exclusion Criteria: Has a current diagnosis of schizophrenia, bipolar disorder, dementia, psychosis, obsessive-compulsive disorder, post-traumatic stress disorder, panic disorder, Attention Deficit Hyperactivity Disorder (ADHD), anorexia nervosa and/or bulimia nervosa, or a history of ADHD, anorexia nervosa and/or bulimia nervosa Agitated during the current depressive episode Has significant abnormal personality traits, which could interfere with function Has a history of substance abuse and or dependence within 6 months prior to screening